Lipidomics Unveils Critical Lipid Pathway Shifts in Alport Syndrome
Belén Requena(Universidad San Pablo CEU), Gema Fernández‐Juárez(Hospital Universitario La Paz), Amir Shabaka(Hospital Universitario Fundación Alcorcón), Carolina González-Riaño(Universidad San Pablo CEU), Teresa Bada-Bosch(Hospital Universitario 12 De Octubre), Sara Martı́nez-Martı́nez(Universidad San Pablo CEU), Gema Medina‐Gómez(Universidad Rey Juan Carlos), Ángel Sevillano(Hospital Universitario 12 De Octubre), Coral Barbas(Universidad San Pablo CEU), Borja Lanzón(Universidad Rey Juan Carlos), Isabel Galán(Hospital Reina Sofía de Murcia), A Tato(Hospital Universitario Fundación Alcorcón)
Cited by 4
Related Papers
PPAR gamma 2 Prevents Lipotoxicity by Controlling Adipose Tissue Expandability and Peripheral Lipid Metabolism
|PLoS Genetics|2007|423
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
|The Lancet Diabetes & Endocrinology|2019|372
COVID-19 in transplant recipients: The Spanish experience
|American Journal of Transplantation|2020|200
Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor γ (PPARγ) and PPARγcoactivator-1 (PGC1)
|Public Health Nutrition|2007|194
Use of tocilizumab in kidney transplant recipients with COVID-19
|American Journal of Transplantation|2020|85